Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (HK:8049)
:8049
Top Page
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
(8049)
Select Model
Select Model
Rating:77Outperform
Price Target:
HK$2.50
▲(15.74% Upside)
Action:ReiteratedDate:10/22/25
The overall score of 77 reflects strong financial performance driven by high profitability and a stable balance sheet as the primary strength. A low P/E ratio adds value appeal, though moderate revenue growth and declining free cash flow pose risks. Technical indicators suggest neutral momentum, contributing less to the score.
Positive Factors
Revenue Growth
Consistent revenue growth indicates a strong market presence and demand for the company's products, supporting long-term financial stability.
Negative Factors
Free Cash Flow Decline
A decline in free cash flow can limit the company's ability to fund new projects or return capital to shareholders, potentially impacting growth and investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Consistent revenue growth indicates a strong market presence and demand for the company's products, supporting long-term financial stability.
Read all positive factors
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.15B
Dividend YieldN/A
Average Volume (3M)47.79K
Price to Earnings (P/E)5.2
Beta (1Y)0.26
Revenue Growth10.26%
EPS Growth6.24%
CountryHK
Employees745
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)N/A
Shares Outstanding172,500,000
10 Day Avg. Volume34,000
30 Day Avg. Volume47,793
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.45
Price to Sales (P/S)0.82
P/FCF Ratio3.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jilin Province Huinan Changlong Bio-pharmacy Company Limited engages in the manufacture and distribution of Chinese medicines and pharmaceutical products in the People's Republic of China. It offers tablets, capsules, pills, Chinese medicine pretr...
How the Company Makes Money
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. generates revenue primarily through the sale of its biopharmaceutical products, including vaccines and therapeutic agents. The company operates on a business model that includes direct sales to...
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
85
Very Positive
Balance Sheet
78
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 926.93M | 881.16M | 841.54M | 841.59M | 705.46M | 622.25M |
| Gross Profit | 731.82M | 685.25M | 584.05M | 648.03M | 580.00M | 530.74M |
| EBITDA | 206.76M | 236.33M | 226.39M | 231.43M | 206.50M | 172.92M |
| Net Income | 182.97M | 184.25M | 148.21M | 193.56M | 143.28M | 126.56M |
Balance Sheet | ||||||
| Total Assets | 2.65B | 2.53B | 2.32B | 2.37B | 2.07B | 1.80B |
| Cash, Cash Equivalents and Short-Term Investments | 748.30M | 539.03M | 655.59M | 1.03B | 262.25M | 283.55M |
| Total Debt | 72.40M | 72.40M | 80.40M | 400.00K | 400.00K | 400.00K |
| Total Liabilities | 915.73M | 901.49M | 838.44M | 760.54M | 618.56M | 459.02M |
| Stockholders Equity | 1.73B | 1.63B | 1.48B | 1.61B | 1.45B | 1.35B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 208.63M | 284.11M | 192.68M | 122.25M | 52.46M |
| Operating Cash Flow | 0.00 | 219.65M | 315.95M | 203.99M | 215.09M | 151.23M |
| Investing Cash Flow | 0.00 | -310.93M | 109.04M | -117.97M | -160.61M | -244.85M |
| Financing Cash Flow | 0.00 | -25.01M | -186.45M | -27.71M | -25.20M | -17.75M |
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis
Positive
2.16
Price Trends
2.08
Positive
2.14
Negative
2.14
Negative
Market Momentum
<0.01
Positive
52.45
Neutral
43.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.16 is above the 20-day moving average (MA) of 2.09, above the 50-day MA of 2.08, and above the 200-day MA of 2.14, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 52.45 is Neutral, neither overbought nor oversold. The STOCH value of 43.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$1.15B | 5.18 | 10.88% | ― | 10.26% | 6.24% | |
72 Outperform | HK$2.11B | 5.29 | 20.10% | 9.98% | 12.83% | 36.12% | |
68 Neutral | HK$660.66M | 20.07 | 1.87% | 9.43% | -1.99% | -81.52% | |
66 Neutral | HK$1.68B | 4.06 | 5.33% | 5.16% | 2.89% | -68.83% | |
64 Neutral | HK$736.04M | 6.31 | 5.44% | 2.92% | 19.80% | 55.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$1.02B | -2.84 | -48.86% | ― | -43.46% | -96.48% |
* Healthcare Sector Average
HK:8049
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
2.10
0.65
44.93%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.25
-0.13
-9.42%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.39
1.11
396.43%
HK:2161
JBM (Healthcare) Ltd.
2.65
0.97
57.74%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.12
>-0.01
-0.88%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.78
-0.10
-11.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.